HK1202086A1 - Calcimimetics and methods for their use - Google Patents

Calcimimetics and methods for their use Download PDF

Info

Publication number
HK1202086A1
HK1202086A1 HK15102648.5A HK15102648A HK1202086A1 HK 1202086 A1 HK1202086 A1 HK 1202086A1 HK 15102648 A HK15102648 A HK 15102648A HK 1202086 A1 HK1202086 A1 HK 1202086A1
Authority
HK
Hong Kong
Prior art keywords
methods
calcimimetics
effective
levels
kidney disease
Prior art date
Application number
HK15102648.5A
Other languages
English (en)
Chinese (zh)
Inventor
Sarah Walter
Gregory Bell
James E. Tomlinson
Original Assignee
Kai Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47258113&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1202086(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kai Pharmaceuticals, Inc. filed Critical Kai Pharmaceuticals, Inc.
Publication of HK1202086A1 publication Critical patent/HK1202086A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK15102648.5A 2011-11-10 2012-11-12 Calcimimetics and methods for their use HK1202086A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161558389P 2011-11-10 2011-11-10
US201161558389P 2011-11-10
PCT/US2012/064717 WO2013071262A1 (en) 2011-11-10 2012-11-12 Calcimimetics and methods for their use

Publications (1)

Publication Number Publication Date
HK1202086A1 true HK1202086A1 (en) 2015-09-18

Family

ID=47258113

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15102648.5A HK1202086A1 (en) 2011-11-10 2012-11-12 Calcimimetics and methods for their use

Country Status (9)

Country Link
US (3) US20140315809A1 (enExample)
EP (1) EP2776129B2 (enExample)
JP (2) JP6204369B2 (enExample)
CN (2) CN104168955A (enExample)
AU (1) AU2012335009B2 (enExample)
CA (1) CA2854911C (enExample)
HK (1) HK1202086A1 (enExample)
MX (1) MX355063B (enExample)
WO (1) WO2013071262A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2887039T3 (es) 2004-04-21 2021-12-21 Alexion Pharma Inc Conjugados para administración ósea y procedimiento de uso de estos para dirigir proteínas al hueso
RU2557654C3 (ru) 2009-07-29 2017-07-05 Каи Фармасьютикалз, Инк. Терапевтические агенты для снижения уровней паратиреоидного гормона
EA030220B1 (ru) 2013-06-28 2018-07-31 Эмджен Инк. Устойчивая жидкая композиция, содержащая amg-416 (этелкалцетид)
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
WO2016062277A1 (zh) * 2014-10-24 2016-04-28 朗齐生物医学股份有限公司 驱虫药用于制备抗癌医药组合物中的应用
BR112017011900A2 (pt) 2014-12-05 2018-02-27 Alexion Pharma Inc tratamento de ataques com fosfatase alcalina recombinante
US9539264B2 (en) 2014-12-30 2017-01-10 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics
CA2973883A1 (en) * 2015-01-28 2016-08-04 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
AU2016308624B2 (en) 2015-08-17 2022-06-23 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
JP6868617B2 (ja) 2015-09-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ（ｔｎｓａｌｐ）酵素補充療法に有効な投薬計画の特定
WO2017074466A1 (en) 2015-10-30 2017-05-04 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
CN106928320B (zh) * 2015-12-31 2021-01-15 深圳翰宇药业股份有限公司 一种合成Etelcalcetide的方法
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
US11186832B2 (en) 2016-04-01 2021-11-30 Alexion Pharmaceuticals, Inc. Treating muscle weakness with alkaline phosphatases
WO2017173395A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
JP7018933B2 (ja) 2016-08-18 2022-02-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド 気管気管支軟化症の治療方法
CN110719786A (zh) 2017-03-31 2020-01-21 阿雷克森制药公司 用于治疗成人和青少年的低磷酸酯酶症(hpp)的方法
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase
EP3833377B1 (en) 2018-08-10 2023-11-22 Alexion Pharmaceuticals, Inc. Bone healing at implants using alkaline phosphatase
EP3867650A1 (en) * 2018-10-18 2021-08-25 Fresenius Medical Care Holdings, Inc. Techniques for modeling parathyroid gland functionality and calcimimetic drug activity
BR112022011127A2 (pt) * 2019-12-09 2022-08-23 Beijing Tuo Jie Biopharmaceutical Co Ltd Composto agonista do receptor de detecção de cálcio e aplicação do mesmo
MX2022007114A (es) 2019-12-09 2022-07-11 Alexion Pharma Inc Polipeptidos de fosfatasa alcalina y metodos de uso de los mismos.
AU2021338639B2 (en) * 2020-09-10 2024-05-23 Shaanxi Micot Pharmaceutical Technology Co., Ltd. Bispecific fusion polypeptide compound
BR112023016048A2 (pt) 2021-02-12 2023-11-14 Alexion Pharma Inc Polipeptídeos de fosfatase alcalina e métodos de uso dos mesmos
CN117295510A (zh) * 2021-06-08 2023-12-26 北京拓界生物医药科技有限公司 一种钙敏感受体激动剂的组合物及其应用
CN117500820A (zh) * 2021-06-08 2024-02-02 北京拓界生物医药科技有限公司 钙敏感受体激动剂化合物的盐酸盐及药物组合物和其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602116A (en) 1988-08-02 1997-02-11 Bone Care International, Inc. Method for treating and preventing secondary hyperparathyroidism
US5869473A (en) 1988-08-02 1999-02-09 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
CA1333616C (en) 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
US5246925A (en) 1989-03-09 1993-09-21 Wisconsin Alumni Research Foundation 19-nor-vitamin D compounds for use in treating hyperparathyroidism
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US6011068A (en) 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6031003A (en) 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US6147186A (en) * 1996-07-31 2000-11-14 The General Hospital Corporation Parathyroid hormone-related peptide analogs
US6274169B1 (en) 1999-08-02 2001-08-14 Abbott Laboratories Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol
US6051567A (en) 1999-08-02 2000-04-18 Abbott Laboratories Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol
EP2070911A2 (en) 2000-07-18 2009-06-17 Bone Care International, Inc. Stabilized 1Alpha-Hydroxy vitamin D
US6998404B2 (en) * 2001-08-08 2006-02-14 Genomed, Llc Treatment or prevention of acute renal failure
MX2007011153A (es) * 2005-03-17 2007-12-12 Amgen Inc Metodos para reducir la calcificacion.
WO2008067199A2 (en) 2006-11-16 2008-06-05 Kai Pharmaceuticals, Inc. Polycationic calcium modulator peptides for the treatment of hyperparathyroidism and hypercalcemic disorders
US20080261926A1 (en) * 2007-04-02 2008-10-23 Liu Julie F Pharmaceutical Calcimimetics
RU2557654C3 (ru) * 2009-07-29 2017-07-05 Каи Фармасьютикалз, Инк. Терапевтические агенты для снижения уровней паратиреоидного гормона
GB0913525D0 (en) * 2009-08-03 2009-09-16 Ineos Healthcare Ltd Method

Also Published As

Publication number Publication date
US20170252397A1 (en) 2017-09-07
EP2776129A1 (en) 2014-09-17
CN104168955A (zh) 2014-11-26
CN109985228A (zh) 2019-07-09
EP2776129B1 (en) 2017-03-29
US20160175383A1 (en) 2016-06-23
CA2854911A1 (en) 2013-05-16
JP2017160269A (ja) 2017-09-14
CA2854911C (en) 2019-09-24
AU2012335009A1 (en) 2014-05-29
EP2776129B2 (en) 2020-06-17
WO2013071262A1 (en) 2013-05-16
AU2012335009B2 (en) 2017-08-31
JP2015502346A (ja) 2015-01-22
MX2014005662A (es) 2014-11-10
JP6204369B2 (ja) 2017-09-27
US20140315809A1 (en) 2014-10-23
MX355063B (es) 2018-04-04

Similar Documents

Publication Publication Date Title
HK1202086A1 (en) Calcimimetics and methods for their use
BR112015009948A2 (pt) antagonistas de ativina-actriia e usos para tratamento ósseos e outros disturbios
BR112015003397A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
WO2015171610A3 (en) Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
PH12015502275B1 (en) Therapuetic uses of empagliflozin
EA201270803A1 (ru) Тиоацетатные соединения, композиции на их основе и способы их применения
CO6791571A2 (es) Moduladores de la proteína tirosina quinasa 7 (ptk7) para el tratamiento diagnóstico o profilaxis de trastornos neoplásicos
EA201692001A1 (ru) Способ получения amg 416
BR112015003332A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112015003398A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
WO2014015157A3 (en) Sigma receptor ligands for modulating cellular protein homeostasis
HK1211525A1 (en) Laquinimod and pridopidine for treating neurodegenerative disorders
WO2012103038A3 (en) Nanoparticle compositions, formulations thereof, and uses therefor
BR112015009216A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de uma composição farmacêutica
EA201270767A1 (ru) Терапия на основе лигандов хемосенсорных рецепторов
WO2012149478A3 (en) Agents useful for treating friedreich's ataxia and other neurodegenerative diseases
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
WO2009006548A3 (en) Treatment for anxiety
MX2020010004A (es) Composicion farmaceutica que comprende empagliflozina, metodos para tratamiento y sus usos.
WO2014205302A3 (en) Lectin-like oxidized ldl receptor1 antibodies and methods of use
BR112018072401A2 (pt) combinações de linagliptina e metformina
WO2014099633A3 (en) Inhibitors of the renal outer medullary potassium channel
EP4279127A3 (en) Growth differentiation factor 15 as biomarker for metformin
WO2012125408A8 (en) Pegylated apelin and uses thereof
BR112013012212A2 (pt) método para tratar doença renal crônica ou doenças degenerativas relacionadas à idade do paciente